Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear
Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis. The post Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear appeared first on MedCity News.
Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis.
The post Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear appeared first on MedCity News.
